Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





GLUTARALDEHYDE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 111-30-8; **Chemical Formula:** OCH(CH2)3CHO
OSHA previously had no limit for glutaraldehyde and proposed establishing a ceiling limit of 0.2 ppm, based on the ACGIH (1986/Ex. 1-3) recommendation. NIOSH (Ex. 8-47, Table N1) concurred with this proposal, and the final rule establishes this limit. Glutaraldehyde is an aliphatic dialdehyde that forms colorless crystals.
Glutaraldehyde is strongly irritating to the nose, eyes, and skin (Human Sensory Irritation Threshold of Glutaraldehyde Vapor 1976, as cited in ACGIH 1986/Ex. 1-3, p. 285) and can cause allergic contact dermatitis from occasional or incidental occupational exposure (Jordan, Dahl, and Albert 1972/ Ex. 1-1056). The rat oral LD(50) has been variously reported as 250, 820, and 2380 mg/kg (Stonehill, Krop, and Borick 1963/Ex. 1-1066; Smyth 1963 and NIOSH 1975f, both as cited in ACGIH 1986/Ex. 1-3, p. 285). The dermal LC(50) in the rabbit is 2560 mg/kg, and the 4-hour inhalation LD(50) in the rat is 5000 ppm (NIOSH 1975f, as cited in ACGIH 1986/Ex. 1-3, p. 285).
Mice exposed to alkalinized glutaraldehyde at 8 and 33 ppm for 24 hours have shown marked nervous behavior with panting and compulsive washing of the face and limbs; those exposed to 33 ppm exhibited signs of toxic hepatitis at autopsy (Varpela, Otterstrom, and Hackman 1971/Ex. 1-1072).
In a study of a cold-sterilizing operation in which the operator was exposed for 12 minutes to an activated 2-percent aqueous solution, a measurement of 0.38 ppm glutaraldehyde was taken in the operator’s breathing zone; the operator and the investigators experienced severe eye, nose, and throat irritation as well as sudden headache at the end of this procedure (Schneider and Blejer 1973, as cited in ACGIH 1986/Ex. 1-3, p. 285). Another study employing very precise methods of airborne concentration measurement reported the irritation response level for glutaraldehyde to be 0.3 ppm and the odor recognition threshold to be 0.04 ppm (Colwell 1976, as cited in ACGIH 1986/Ex. 1-3, p. 285).
Other than the NIOSH submission, OSHA received no comments on its proposal to establish a ceiling level of 0.2 ppm for glutaraldehyde. The Agency finds that the human evidence cited above clearly demonstrates a significant risk of irritation to the eyes, nose, and throat associated with short-term exposures to glutaraldehyde at concentrations of 0.3 ppm or above. OSHA consides the irritation effects associated with exposure to glutaraldehyde to be material impairments of health. Therefore, OSHA is establishing a 0.2-ppm ceiling limit for this substance in the final rule.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue